Clinical trialPhase 1 / Phase 2Completed
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
- Outcome
- Outcome unknown
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- May 2013
- Expected end
- 1 October 2017
- Enrollment
- 25 participants
- Sites
- 3
- Primary outcomes
- Complete Response Rate
- Sponsor
- Other
- Results posted
- 2019-05-29
- Last update
- 29 May 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- Builds on itResponse Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced… DOI 10.1001/jamaoncol.2019.3394↗
- BackgroundGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. DOI 10.1200/jco.2011.36.5742↗